Chronic atrophic gastritis: focus on diagnosis

Abstract

Currently, chronic atrophic gastritis is a risk factor for the development of gastric cancer. Data on the prevalence of chronic atrophic gastritis in Russia and the world are limited. Among the adult population of St. Petersburg aged 21 to 81 years, the prevalence of histologically verified chronic atrophic gastritis is 5.3%. Moreover, the chances of developing chronic atrophic gastritis in people over the age of 60 years compared to the group of 45–59 years are 2.5 times higher (95% confidence interval 1.5–4.1).

Morphological verification of the Operative Link for Gastritis Assessment diagnosis is not carried out in clinical practice in most cases. However, this method remains the most reliable method for timely verification of chronic atrophic gastritis, including chronic atrophic gastritis of mixed origin (autoimmune gastritis and Helicobacter pylori-associated gastritis), especially in the case of a seronegative variant of autoimmune gastritis.

Also, in addition to the heterogeneity of epidemiological data on chronic atrophic gastritis, there is disagreement about how to confirm its etiology as well as about the correlation of serological markers of atrophy and histological stage.

Keywords

chronic atrophic gastritis / atrophy of the gastric mucosa / intestinal metaplasia / cancer screening for gastric cancer / diagnosis of Helicobacter pylori

References

[1] Bakulin IG, Sushilova AG, Zharkov AV. The effectiveness of including screening for chronic atrophic gastritis and Helicobacter pylori infection in clinical examination programs. Therapy. 2023;9(7):8–14. (In Russ.) DOI: 10.18565/therapy.2023.7.8-14

[2] Бакулин И.Г., Сушилова А.Г., Жарков А.В. Эффективность включения скрининга хронического атрофического гастрита и инфекции Helicobacter pylori в программы диспансеризации // Терапия. 2023. Т. 9, № 7. С. 8–14. DOI: 10.18565/therapy.2023.7.8-14

[3] Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology. 2021;161(4):1325–1332.e7. DOI: 10.1053/j.gastro.2021.06.078

[4] Shah S.C., Piazuelo M.B., Kuipers E.J., Li D. AGA Clinical practice update on the diagnosis and management of atrophic gastritis: expert review // Gastroenterology. 2021. Vol. 161, No. 4. P. 1325–1332.e7. DOI: 10.1053/j.gastro.2021.06.078

[5] Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. DOI: 10.1136/gutjnl-2015-309252

[6] Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis // Gut. 2015. Vol. 64, No. 9. P. 1353–1367. DOI: 10.1136/gutjnl-2015-309252

[7] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. DOI: 10.1002/ijc.33588

[8] Ferlay J., Colombet M., Soerjomataram I. et al. Cancer statistics for the year 2020: an overview // Int. J. Cancer. 2021. DOI: 10.1002/ijc.33588

[9] Kaprin AD, Starinsky VV, Shakhzadova AO. The state of oncological care for the population of Russia in 2020. Moscow; 2021. 239 p. Available from: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf. Accessed: 11.09.2023. (In Russ.)

[10] Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2020 году Москва, 2021. 239 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf. Дата обращения: 11.09.2023.

[11] Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745

[12] Malfertheiner P., Megraud F., Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report // Gut. 2022:gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745

[13] Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United Eur Gastroenterol J. 2018;6(2):192–202. DOI: 10.1177/2050640617722902

[14] Areia M., Spaander M.C., Kuipers E.J., Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk // United Eur. Gastroenterol. J. 2018. Vol. 6, No. 2. P. 192–202. DOI: 10.1177/2050640617722902

[15] Carabotti M, Annibale B, Lahner E. Common pitfalls in the management of patients with micronutrient deficiency: keep in mind the stomach. Nutrients. 2021;13(1):208. DOI: 10.3390/nu13010208

[16] Carabotti M., Annibale B., Lahner E. Common pitfalls in the management of patients with micronutrient deficiency: keep in mind the stomach // Nutrients. 2021. Vol. 13, No. 1. P. 208. DOI: 10.3390/nu13010208

[17] Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primer. 2020;6(1):56. DOI: 10.1038/s41572-020-0187-8

[18] Lenti M.V., Rugge M., Lahner E. et al. Autoimmune gastritis // Nat. Rev. Dis. Primer. 2020. Vol. 6, No. 1. P. 56. DOI: 10.1038/s41572-020-0187-8

[19] Park JY, Cornish TC, Lam-Himlin D, et al. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting. Am J Surg Pathol. 2010;34(11):1591–1598. DOI: 10.1097/PAS.0b013e3181f623af

[20] Park J.Y., Cornish T.C., Lam-Himlin D. et al. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting // Am. J. Surg. Pathol. 2010. Vol. 34, No. 11. P. 1591–1598. DOI: 10.1097/PAS.0b013e3181f623af

[21] Bakulina N, Tikhonov S, Malkov V, et al. Non-invasive screening of autoimmune atrophic gastritis in asymptomatic subjects by Serological Biomarker Test (GastroPanel®). Anticancer Res. 2022;42(3):1517–1526. DOI: 10.21873/anticanres.15624

[22] Bakulina N., Tikhonov S., Malkov V. et al. Non-invasive screening of autoimmune atrophic gastritis in asymptomatic subjects by Serological Biomarker Test (GastroPanel®) // Anticancer Res. 2022. Vol. 42, No. 3. P. 1517–1526. DOI: 10.21873/anticanres.15624

[23] Zhang H, Jin Z, Cui R, et al. Autoimmune metaplastic atrophic gastritis in chinese: a study of 320 patients at a large tertiary medical center. Scand J Gastroenterol. 2017;52(2):150–156. DOI: 10.1080/00365521.2016.1236397

[24] Zhang H., Jin Z., Cui R. et al. Autoimmune metaplastic atrophic gastritis in chinese: a study of 320 patients at a large tertiary medical center // Scand. J. Gastroenterol. 2017. Vol. 52, No. 2. P. 150–156. DOI: 10.1080/00365521.2016.1236397

[25] Notsu T, Adachi K, Mishiro T, et al. Prevalence of autoimmune gastritis in individuals undergoing medical checkups in Japan. Intern Med Tokyo Jpn. 2019;58(13):1817–1823. DOI: 10.2169/internalmedicine.2292-18

[26] Notsu T., Adachi K., Mishiro T. et al. Prevalence of autoimmune gastritis in individuals undergoing medical checkups in Japan // Intern. Med. Tokyo Jpn. 2019. Vol. 58, No. 13. P. 1817–1823. DOI: 10.2169/internalmedicine.2292-18

[27] Massironi S, Zilli A, Elvevi A, Invernizzi P. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmun Rev. 2019;18(3):215–222. DOI: 10.1016/j.autrev.2018.08.011

[28] Massironi S., Zilli A., Elvevi A., Invernizzi P. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective // Autoimmun. Rev. 2019. Vol. 18, No. 3. P. 215–222. DOI: 10.1016/j.autrev.2018.08.011

[29] Tsukanov VV, Tret’yakova OV, Amelchugova OS, et al. The prevalence of atrophic gastritis of the body of stomach at Krasnoyarsk population over 45 years old. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(4):27–31. (In Russ.)

[30] Цуканов В.В., Третьякова О.В., Амельчугова О.С. и др. Распространенность атрофического гастрита тела желудка у населения г. Красноярска старше 45 лет // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012. Т. 22, № 4. С. 27–31.

[31] Bakulin IG, Sushilova AG, Serkova MYu. The role of non-invasive screening in assessing the burden of chronic atrophic gastritis. Preventive medicine. 2023;26(5-2):59. (In Russ.)

[32] Бакулин И.Г., Сушилова А.Г., Серкова М.Ю. Роль неинвазивного скрининга в оценке бремени хронического атрофического гастрита // Профилактическая Медицина. 2023. Т. 26, № 5-2. С. 59.

[33] Haziri A, Juniku-Shkololli A, Gashi Z, et al. Helicobacter pylori infection and precancerous lesions of the stomach. Med Arh. 2010;64(4):248–249.

[34] Haziri A., Juniku-Shkololli A., Gashi Z. et al. Helicobacter pylori infection and precancerous lesions of the stomach // Med. Arh. 2010. Vol. 64, No. 4. P. 248–249.

[35] Chen S, Ying L, Kong M, et al. The Prevalence of Нelicobacter pylori infection decreases with older age in atrophic gastritis. Gastroenterol Res Pract. 2013;2013:494783. DOI: 10.1155/2013/494783

[36] Chen S., Ying L., Kong M. et al. The Prevalence of Helicobacter pylori infection decreases with older age in atrophic gastritis // Gastroenterol. Res. Pract. 2013. Vol. 2013. P. 494783. DOI: 10.1155/2013/494783

[37] Roman LD, Lukyanchuk R, Sablin OA, et al. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg. Anticancer Res. 2016;36(8):4129–4138.

[38] Roman L.D., Lukyanchuk R., Sablin O.A. et al. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg // Anticancer Res. 2016. Vol. 36, No. 8. P. 4129–4138.

[39] Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in Russia: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI: 10.1111/hel.12924

[40] Bordin D., Morozov S., Plavnik R. et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in Russia: The data of real-world national multicenter trial // Helicobacter. 2022. Vol. 27, No. 5. P. e12924. DOI: 10.1111/hel.12924

[41] Bakulina NV, Simanenkov VI, Bakulin IG, Ilchishina TA. Prevalence of Нelicobacter pylori infection among physicians. Experimental and Clinical Gastroenterology. 2017;(12):20–24. (In Russ.)

[42] Бакулина Н.В., Симаненков В.И., Бакулин И.Г., Ильчишина Т.А. Распространенность хеликобактерной инфекции среди врачей // Экспериментальная и клиническая гастроэнтерология. 2017. № 12. С. 20–24.

[43] Zaharova NV, Simanenkov VI, Bakulin IG, et al. Prevalence of Нelicobacter pylori infection in gastroenterological patients in Saint Petersburg. Pharmateka. 2016;(5S):33–39. (In Russ.)

[44] Захарова Н.В., Симаненков В.И., Бакулин И.Г. и др. Распространенность хеликобактерной инфекции у пациентов гастроэнтерологического профиля в Санкт-Петербурге // Фарматека. 2016. № 5S. С. 33–39.

[45] Price AB. The Sydney system: histological division. J Gastroenterol Hepatol. 1991;6(3):209–222. DOI: 10.1111/j.1440-1746.1991.tb01468.x

[46] Price A.B. The Sydney system: histological division // J. Gastroenterol. Hepatol. 1991. Vol. 6, No. 3. P. 209–222. DOI: 10.1111/j.1440-1746.1991.tb01468.x

[47] Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–1181. DOI: 10.1097/00000478-199610000-00001

[48] Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994 // Am. J. Surg. Pathol. 1996. Vol. 20, No. 10. P. 1161–1181. DOI: 10.1097/00000478-199610000-00001

[49] Rugge M, de Boni M, Pennelli G, et al. OLGA can guard the barn. Am J Gastroenterol. 2009;104(12):3099. DOI: 10.1038/ajg.2009.512

[50] Rugge M., de Boni M., Pennelli G. et al. OLGA can guard the barn // Am. J. Gastroenterol|. 2009. Vol. 104, No. 12. P. 3099. DOI: 10.1038/ajg.2009.512

[51] Rugge M, Fassan M, Pizzi M, et al. Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol. 2011;42(10):1539–1544. DOI: 10.1016/j.humpath.2010.12.017

[52] Rugge M., Fassan M., Pizzi M. et al. Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping // Hum. Pathol. 2011. Vol. 42, No. 10. P. 1539–1544. DOI: 10.1016/j.humpath.2010.12.017

[53] Orgler E, Dabsch S, Malfertheiner P, Schulz C. Autoimmune gastritis: update and new perspectives in therapeutic management. Curr Treat Options Gastroenterol. 2023;21(1):64–77. DOI: 10.1007/s11938-023-00406-4

[54] Orgler E., Dabsch S., Malfertheiner P., Schulz C. Autoimmune gastritis: update and new perspectives in therapeutic management // Curr. Treat Options Gastroenterol. 2023. Vol. 21, No. 1. P. 64–77. DOI: 10.1007/s11938-023-00406-4

[55] Livzan MA, Gaus OV, Mozgovoi SI, Bordin DS. Chronic autoimmune gastritis: modern diagnostic principles. Diagnostics. 2021;11(11):2113. DOI: 10.3390/diagnostics11112113

[56] Livzan M.A., Gaus O.V., Mozgovoi S.I., Bordin D.S. Chronic autoimmune gastritis: modern diagnostic principles // Diagnostics. 2021. Vol. 11, No. 11. P. 2113. DOI: 10.3390/diagnostics11112113

[57] Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–388. DOI: 10.1055/a-0859-1883

[58] Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019 // Endoscopy. 2019. Vol. 51, No. 4. P. 365–388. DOI: 10.1055/a-0859-1883

[59] Vaiphei K. Interpretation of endoscopic biopsy. In: Interpretation of Endoscopic Biopsy — Gastritis, Gastropathies and Beyond. Springer; 2022. P. 19–29. DOI: 10.1007/978-981-16-6026-9_4

[60] Vaiphei K. Interpretation of endoscopic biopsy // Interpretation of Endoscopic Biopsy — Gastritis, Gastropathies and Beyond. Springer; 2022. P. 19–29. DOI: 10.1007/978-981-16-6026-9_4

[61] Livzan MA, Krolevets TS, Mozgovoy SI, et al. Autoimmune gastritis: from symptom to diagnosis. Clinical observations. Consilium Medicum. 2020;22(8):78–84. (In Russ.)

[62] Ливзан М.А., Кролевец Т.С., Мозговой С.И. и др. Аутоиммунный гастрит: от симптома к диагнозу. Клинические наблюдения // Consilium Medicum. 2020. Т. 22, № 8. С. 78–84.

[63] Coati I, Fassan M, Farinati F, et al. Autoimmune gastritis: Pathologist’s viewpoint. World J Gastroenterol. 2015;21(42):12179–12189. DOI: 10.3748/wjg.v21.i42.12179

[64] Coati I., Fassan M., Farinati F. et al. Autoimmune gastritis: Pathologist’s viewpoint // World J. Gastroenterol. 2015. Vol. 21, No. 42. P. 12179–12189. DOI: 10.3748/wjg.v21.i42.12179

[65] Maev IV, Zajrat’yanc OV, Kucheryavyj YuA. Kishechnaya metaplaziya slizistoj obolochki zheludka v praktike gastroenterologa: sovremennyj vzglyad na problemu. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(4):38–48. (In Russ.)

[66] Маев И.В., Зайратьянц О.В., Кучерявый Ю.А. Кишечная метаплазия слизистой оболочки желудка в практике гастроэнтеролога: современный взгляд на проблему // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006. Т. 16, № 4. С. 38–48.

[67] Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54(6):764–768. DOI: 10.1136/gut.2004.055400

[68] Watabe H., Mitsushima T., Yamaji Y. et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study // Gut. 2005. Vol. 54, No. 6. P. 764–768. DOI: 10.1136/gut.2004.055400

[69] Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657–667. DOI: 10.1111/apt.14248

[70] Zagari R.M., Rabitti S., Greenwood D.C. et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis // Aliment. Pharmacol. Ther. 2017. Vol. 46, No. 7. P. 657–667. DOI: 10.1111/apt.14248

[71] Koivurova OP, Koskela R, Blomster T, et al. Serological biomarker panel in diagnosis of atrophic gastritis and Нelicobacter pylori infection in gastroscopy referral patients: Clinical Validation of the New-Generation GastroPanel® Test. Anticancer Res. 2021;41(11):5527–5537. DOI: 10.21873/anticanres.15366

[72] Koivurova O.P., Koskela R., Blomster T. et al. Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients: Clinical Validation of the New-Generation GastroPanel® Test // Anticancer Res. 2021. Vol. 41, No. 11. P. 5527–5537. DOI: 10.21873/anticanres.15366

[73] Kurilovich SA, Belkovec AV, Reshetnikov OV, et al. Prognostic value of the atrophia markers in gastric cancer risk at the west Siberia population (prospective “case-control study”). Experimental and Clinical Gastroenterology. 2017;147(11):13–21. (In Russ.)

[74] Курилович С.А., Белковец А.В., Решетников О.В. и др. Прогностическая значимость маркеров атрофии в развитии рака желудка в популяции Западной Сибири // Экспериментальная и клиническая гастроэнтерология. 2017. Т. 147, № 11. С. 13–21.

[75] Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci. 2011;56(2):145–150. DOI: 10.2478/v10039-011-0040-0

[76] Leja M., Kupcinskas L., Funka K. et al. Value of gastrin-17 in detecting antral atrophy // Adv. Med. Sci. 2011. Vol. 56, No. 2. P. 145–150. DOI: 10.2478/v10039-011-0040-0

[77] Hall SN, Appelman HD. Autoimmune gastritis. Arch Pathol Lab Med. 2019;143(11):1327–1331. DOI: 10.5858/arpa.2019-0345-RA

[78] Hall S.N., Appelman H.D. Autoimmune gastritis // Arch. Pathol. Lab. Med. 2019. Vol. 143, No. 11. P. 1327–1331. DOI: 10.5858/arpa.2019-0345-RA

[79] Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20(6):1438–1449. DOI: 10.3748/wjg.v20.i6.1438

[80] Garza-González E., Perez-Perez G.I., Maldonado-Garza H.J., Bosques-Padilla F.J. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication // World J. Gastroenterol. 2014. Vol. 20, No. 6. P. 1438–1449. DOI: 10.3748/wjg.v20.i6.1438

[81] Best LM, Takwoingi Y, Siddique S, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3):CD012080. DOI: 10.1002/14651858.CD012080.pub2

[82] Best L.M., Takwoingi Y., Siddique S. et al. Non-invasive diagnostic tests for Helicobacter pylori infection // Cochrane Database Syst. Rev. 2018. Vol. 3, No. 3. P. CD012080. DOI: 10.1002/14651858.CD012080.pub2

[83] Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015;3(1):9. DOI: 10.3978/j.issn.2305-5839.2014.12.04

[84] Uotani T., Graham D.Y. Diagnosis of Helicobacter pylori using the rapid urease test // Ann. Transl. Med. 2015. Vol. 3, No. 1. P. 9. DOI: 10.3978/j.issn.2305-5839.2014.12.04

[85] Gong RJ, Xu CX, Li H, Liu XM. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases. 2021;9(1):133–147. DOI: 10.12998/wjcc.v9.i1.133

[86] Gong R.J., Xu C.X., Li H., Liu X.M. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: a meta-analysis // World J. Clin. Cases. 2021. Vol. 9, No. 1. P. 133–147. DOI: 10.12998/wjcc.v9.i1.133

[87] Shimoyama T, Oyama T, Matsuzaka M, et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey. Helicobacter. 2009;14(2):87–90. DOI: 10.1111/j.1523-5378.2009.00672.x

[88] Shimoyama T., Oyama T., Matsuzaka M. et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey // Helicobacter. 2009. Vol. 14, No. 2. P. 87–90. DOI: 10.1111/j.1523-5378.2009.00672.x

[89] Cardos AI, Maghiar A, Zaha DC, et al. Evolution of diagnostic methods for Нelicobacter pylori infections: From traditional tests to high technology, advanced sensitivity and discrimination tools. Diagn Basel Switz. 2022;12(2):508. DOI: 10.3390/diagnostics12020508

[90] Cardos A.I., Maghiar A., Zaha D.C. et al. Evolution of diagnostic methods for Нelicobacter pylori infections: From traditional tests to high technology, advanced sensitivity and discrimination tools // Diagn. Basel Switz. 2022. Vol. 12, No. 2. P. 508. DOI: 10.3390/diagnostics12020508

[91] Chmiela M, Gonciarz W. Molecular mimicry in Helicobacter pylori infections. World J Gastroenterol. 2017;23(22):3964–3977. DOI: 10.3748/wjg.v23.i22.3964

[92] Chmiela M., Gonciarz W. Molecular mimicry in Helicobacter pylori infections // World J. Gastroenterol. 2017. Vol. 23, No. 22. P. 3964–3977. DOI: 10.3748/wjg.v23.i22.3964

[93] Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.) DOI: 10.22416/1382-4376-2021-31-4-70-99

[94] Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021. Т. 31, № 4. С. 70–99. DOI: 10.22416/1382-4376-2021-31-4-70-99

RIGHTS & PERMISSIONS

Eco-Vector